Company news

Defence Therapeutics Inc news in 2026

Defence Therapeutics Inc's news releases, calls and decks from 2026, newest first.

View company

Defence Therapeutics Announces Convertible Debenture Interest Payment

October 23, 2026

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

October 19, 2026

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

October 1, 2026

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

September 29, 2026

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

September 28, 2026

Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

September 8, 2026

Defence Therapeutics Provides Updates on Sharing Agreement

September 4, 2026

Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs

August 31, 2026

Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs

August 17, 2026

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

August 4, 2026

Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

July 8, 2026

Defence Therapeutics Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform

July 6, 2026

Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors

June 3, 2026

Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors

June 1, 2026

Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian

May 29, 2026

Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

May 19, 2026

Defence Therapeutics Announces Grant of Restricted Stock Units

April 24, 2026

Early warning report filed pursuant to National Instrument 62-103

March 27, 2026

Defence Therapeutics Announces Warrant Terms Amendment

March 20, 2026

Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

March 9, 2026

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

March 2, 2026

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

February 27, 2026

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

February 10, 2026

Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

February 4, 2026

Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

January 28, 2026

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics

January 21, 2026

Decks in 2026